Zhengxiao Zhao

Zhengxiao Zhao

Auto-generated profile, based on publicly available information

Zhengxiao Zhao

Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang 310006, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WGWei-Yi Gong
Wei-Yi Gong
ZZZheng-Xiao Zhao
Zheng-Xiao Zhao
BLBao-Jun Liu
Bao-Jun Liu
LLLin-Wei Lu
Lin-Wei Lu
JDJingcheng Dong
Jingcheng Dong

14 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Purpose: We aimed to construct machine learning (ML) radiomics models to predict response to lenvatinib monotherapy for unresectable hepatocellular carcinoma (HCC). Experimental Design: Patients with HCC receiving lenvatinib monotherapy at three institutions were retrospectively identified and assigned to training and external validation cohorts. Tumor response after initiation of lenvatinib was evaluated. Radiomics features were extracted from contrast-enhanced CT images. The K-means clustering algorithm was used to distinguish radiomics-based subtypes. Ten ML radiomics models were constructed and internally validated by 10-fold cross-validation. These models were subsequently verified in an external validation cohort. Results: A total of 109 patients were identified for analysis, namely, 74 in the training cohort and 35 in the external validation cohort. Thirty-two patients showed partial response, 33 showed stable disease, and 44 showed progressive disease. The overall response rate (ORR) was 29.4%, and the disease control rate was 59.6%. A total of 224 radiomics features were extracted, and 25 significant features were identified for further analysis. Two distant radiomics-based subtypes were identified by K-means clustering, and subtype 1 was associated with a higher ORR and longer progression-free survival (PFS). Among the 10 ML algorithms, AutoGluon displayed the highest predictive performance (AUC = 0.97), which was relatively stable in the validation cohort (AUC = 0.93). Kaplan–Meier analysis showed that responders had a better overall survival [HR = 0.21; 95% confidence interval (CI): 0.12–0.36; P < 0.001] and PFS (HR = 0.14; 95% CI: 0.09–0.22; P < 0.001) than nonresponders. Conclusions: Valuable ML radiomics models were constructed, with favorable performance in predicting the response to lenvatinib monotherapy for unresectable HCC.

4 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZZZheng-Xiao Zhao
Zheng-Xiao Zhao
LLLin-Wei Lu
Lin-Wei Lu
JQJian Qiu
Jian Qiu
QLQiu-Ping Li
Qiu-Ping Li
FXFei Xu
Fei Xu
WGWeiyi Gong
Weiyi Gong
Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis

1 January 2017 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
FXFei Xu
Fei Xu
WCWenqiang Cui
Wenqiang Cui
ZZZhengxiao Zhao
Zhengxiao Zhao
WGWeiyi Gong
Weiyi Gong
YWYing Wei
Ying Wei
JDJingcheng Dong
Jingcheng Dong
Our previous studies have shown that Qing‐Re‐Huo‐Xue (QRHX) formulae had significant anti‐inflammatory effects in chronic airway diseases such as asthma and chronic obstructive lung disease. Here, we examined the effects of QRHX on lung cancer cell invasion and the potential associated mechanism(s), mainly polarization of macrophages in the tumor microenvironment. In vivo, QRHX both inhibited tumor growth and decreased the number of tumor‐associated macrophages (TAMs) in mice with lung cancer. Further study indicated that QRHX inhibited cancer‐related inflammation in tumor by decreasing infiltration of TAMs and IL‐6 and TNF‐α production and meanwhile decreased arginase 1 (Arg‐1) expression and increased inducible NO synthase (iNOS) expression. QRHX could markedly inhibit CD31 and VEGF protein expression. Additionally, CXCL12/CXCR4 expression and JAK2/STAT3 phosphorylation were reduced in QRHX treatment group. Thus, we draw that QRHX played a more important role in inhibiting tumor growth by regulating TAMs in mice, which was found to be associated with the inhibition of inflammation and the CXCL12/CXCR4/JAK2/STAT3 signaling pathway.

18 February 2026 in European Journal of Cancer
Verified
Journal Article
Open access
QCQunwei Chen
Qunwei Chen
XFXinyan Feng
Xinyan Feng
JWJingxian Wang
Jingxian Wang
HZHuilin Zhu
Huilin Zhu
ZBZhiyuan Bo
Zhiyuan Bo
ZZZhengxiao Zhao
Zhengxiao Zhao
Advances in sequencing technology have elucidated the complex role of the gut microbiota in hepatocellular carcinoma (HCC). Communication between the gut and the liver occurs via the gut-liver axis, and dysbiosis of the gut microbiota has been implicated in both the promotion and suppression of HCC. Furthermore, through interactions with host metabolism and immune system, the gut microbiota significantly influences treatment responses and prognostic outcomes of HCC. Despite progress in therapeutic strategies, clinical efficacy remains suboptimal, underscoring the need for a deeper understanding of the gut microbiota's role. This review highlights the potential of gut microbiota as novel biomarkers for the diagnosis and prognostic prediction of HCC, and explores its therapeutic implications. We summarize current insights into the molecular mechanisms underlying the gut microbiota-HCC interplay, and emphasize the relationship between gut microbiota and the efficacy of various treatments, including surgery, chemotherapy, radiotherapy, immunotherapy, and targeted agents. Microbiome-targeting interventions like probiotics, fecal microbiota transplantation (FMT), and dietary changes as emerging adjuvant strategies are also discussed in detail to provide potential resources for advancing translational hepatology. Although challenges remain, this review aims to provide valuable perspectives for developing individualized therapeutic strategies in HCC management.

1 April 2023
Verified
Other
Open access
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Essential scripts for each model and the specific parameters of the models.